Overview

Drug-Interaction Study to Evaluate the Effect of Rifampin, a Potent CYP3A4 Inducer, on the Systemic Exposure of Pacritinib in Healthy Subjects

Status:
Completed

Trial end date:
2015-02-01

Target enrollment:

Participant gender:

Summary

The primary objective is to evaluate the effect of rifampin, a potent cytochrome P450 3A4 inducer, at steady-state on the systemic exposure of a single dose of pacritinib in healthy subjects.

Phase:

Phase 1

Details

Lead Sponsor:

CTI BioPharma

Collaborator:

Covance

Treatments:

Cytochrome P-450 CYP3A Inducers
Rifampin